Clinical Trial Update: A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors [Phase 1]

View source ↗

Summary

RemeGen's RC198 is being evaluated in a Phase 1 study across locally advanced unresectable or metastatic solid tumors, including melanoma, urothelial carcinoma,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Carcinoma
• Head and Neck Squamous Cell Carcinoma
• Melanoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma
• Urothelial Carcinoma

Drugs mentioned

• RC198 (RC198)

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Melanoma, Urothelial Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING